Table 5.
Crumb et al., 2016 | Target 1 | Target 2 | Target 3 | Target 4 |
---|---|---|---|---|
2-step Cdrug = IC60,hERG, direct features | ||||
Step1:IC60,hERG/EFTPC | 73 | 60 | 60 | 60 |
Step1:IC60,hERG/EFTPC | 83 | 83 | 70 | 70 |
Step2:% block ICaV | ||||
Step1:IC60,hERG/EFTPC | 80 | 83 | 83 | 76 |
Step2:% block ICaV & INaL | ||||
Step1:IC60,hERG/EFTPC | 80 | 83 | 83 | 76 |
Step2:% block ICaV, INaL & IKs | ||||
2-step Cdrug = IC60,hERG, Derived Features | ||||
Step1:IC60,hERG/EFTPC | 83 | 83 | 83 | 76 |
Step2: Derived features |
Target1: TdP+ = CM1, CH1, R1, R2, R3, and FDA label QT prolongation and torsade warnings. Target 2: TdP+ = CM1 and CM2. Target 3: TdP+ = CM1. Target 4: TdP+ = CM1 and CM3. Row reporting the maximum accuracies obtained using the derived features is reported for comparision with the direct features.